Silverfin false false 31/05/2025 01/06/2024 31/05/2025 Michael Considine 15/05/2024 12 March 2026 The principal activity of the company during the period was that of packaging solutions and supplies for sterile environments. NI715830 2025-05-31 NI715830 bus:Director1 2025-05-31 NI715830 core:CurrentFinancialInstruments 2025-05-31 NI715830 core:ShareCapital 2025-05-31 NI715830 core:RetainedEarningsAccumulatedLosses 2025-05-31 NI715830 core:ImmediateParent core:CurrentFinancialInstruments 2025-05-31 NI715830 core:RemainingRelatedParties core:CurrentFinancialInstruments 2025-05-31 NI715830 core:CurrentFinancialInstruments 1 2025-05-31 NI715830 bus:OrdinaryShareClass1 2025-05-31 NI715830 2024-06-01 2025-05-31 NI715830 bus:FilletedAccounts 2024-06-01 2025-05-31 NI715830 bus:SmallEntities 2024-06-01 2025-05-31 NI715830 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 NI715830 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 NI715830 bus:Director1 2024-06-01 2025-05-31 NI715830 core:CurrentFinancialInstruments 2024-06-01 2025-05-31 NI715830 bus:OrdinaryShareClass1 2024-06-01 2025-05-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: NI715830 (Northern Ireland)

# ATLANTIC CLINICAL PACKAGING UK LTD

### Unaudited Financial Statements
For the financial period ended 31 May 2025
Pages for filing with the registrar

ATLANTIC CLINICAL PACKAGING UK LTD

## Unaudited Financial Statements

For the financial period ended 31 May 2025

Contents

ATLANTIC CLINICAL PACKAGING UK LTD

## STATEMENT OF FINANCIAL POSITION

As at 31 May 2025
ATLANTIC CLINICAL PACKAGING UK LTD

## STATEMENT OF FINANCIAL POSITION (continued)

As at 31 May 2025

| Note | 2025
|  | £
Current assets |  |
Stocks |  | 28,503
Debtors | 3 | 98,416
Cash at bank and in hand |  | 1,972
|  | 128,891
Creditors: amounts falling due within one year | 4 | ( 181,580)
Net current liabilities |  | (52,689)
Total assets less current liabilities |  | (52,689)
Net liabilities |  | ( 52,689)
Capital and reserves |  |
Called-up share capital | 5 | 1
Profit and loss account |  | ( 52,690 )
Total shareholder's deficit |  | ( 52,689)

For the financial period ending 31 May 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The member has not required the Company to obtain an audit of its financial statements for the financial period in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of Atlantic Clinical Packaging UK Ltd (registered number: NI715830) were approved and authorised for issue by the Director on 12 March 2026. They were signed on its behalf by:

Michael Considine Director |

ATLANTIC CLINICAL PACKAGING UK LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial period ended 31 May 2025
ATLANTIC CLINICAL PACKAGING UK LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial period ended 31 May 2025

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.

##### General information and basis of accounting

Atlantic Clinical Packaging UK Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in Northern Ireland. The address of the Company's registered office is 73 Fenaghy Road, Galgorm, Ballymena, BT42 1HW, Northern Ireland, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Going concern

The director has assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The director notes that the business has net liabilities of £52,689. The Company is supported through loans from the Parent Company and inter company . The director has received assurances that the loan facilities will continue to be available for at least 12 months from the date of signing these financial statements and the Parent and inter Company will continue to support the Company. After making enquiries, the director believes that any foreseeable debts can be met for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Reporting period length

Reporting period length is from the date of incorporation 15 May 2024 to 31 May 2025.

##### Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Statement of Financial Position date are reported at the rates of exchange prevailing at that date.
Exchange differences are recognised in the Statement of Income and Retained Earnings in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

##### Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

##### Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

##### Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

##### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

##### Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

##### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

##### Ordinary share capital

The ordinary share capital of the Company is presented as equity.

#### 2. Employees

| 2025
| Number
Monthly average number of persons employed by the Company during the period, including the director | 2

#### 3. Debtors

| 2025
| £
Trade debtors | 98,416

#### 4. Creditors: amounts falling due within one year

| 2025
| £
Trade creditors | 8,879
Amounts owed to Parent undertakings | 15,869
Amounts owed to related parties | 97,074
Accruals | 3,050
Deferred tax liability | 741
Other taxation and social security | 51,849
Other creditors | 4,118
| 181,580

Amounts owed to Group undertakings are repayable on demand and do not bear interest.

#### 5. Called-up share capital

| 2025
| £
Allotted, called-up and fully-paid |
1 Ordinary share of £ 1.00 | 1

#### 6. Related party transactions

Other related party transactions

| 2025
| £
Amounts owed to Parent company | 15,869
Amounts owed to associated company | 42,157
Amounts owed to a related company | 54,917